Low-dose aspirin

ApprovedSmall molecule

PPharmaEssentia Japan K.K.

Low-dose aspirin is one of 270 small molecule programs targeting Polycythemia Vera. It is currently in Approved.

Indications

Total Trials

Active Trials

269

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

MiscarriageActive, not recruiting

Coronary Artery BypassActive, not recruiting

PreeclampsiaActive, not recruiting

Breast CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Ischemic StrokeActive, not recruiting

GrowthActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Acute Coronary SyndromePhase 2

Active, not recruiting

MiscarriagePreclinical

Active, not recruiting

Coronary Artery BypassPhase 3

Active, not recruiting

PreeclampsiaApproved

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Endometrial CancerApproved

Active, not recruiting

Ischemic StrokeApproved

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Low-dose aspirin

PPharmaEssentia Japan K.K.

Approved

1 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Breast Cancer

NCT05557877

Q2 2027

Post-ApprovalRecruiting

Preeclampsia

NCT06281665

Post-ApprovalNot yet recruiting

Endometrial Cancer

NCT07281547

Q3 2027

Phase 3Recruiting

Complication

NCT05198960

Q4 2030

Phase 3Recruiting

Coronary Artery Bypass

NCT07195149

Clinical

Trials by Indication[1]

Preeclampsia5 trials

Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia

Withdrawn·WWomen and Infants Hospital of Rhode Island·Phase 4·NCT04797949

Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)

Completed·UUniversity of Lagos, Nigeria·Phase 3·NCT05253781·476 enrolled

Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)

Terminated·—·Phase 1·NCT04243278·14 enrolled

Show 2 more trials

Hydroxychloroquine in Prevention of Preeclampsia

Completed·—·N/A·NCT04755322·50 enrolled

Treatment With Aspirin After Preeclampsia: TAP Trial

Recruiting·MMalamo Countouris·Phase 4·NCT06281665·60 enrolled

Pregnancy4 trials

The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction

Completed·—·Phase 2·NCT02696577·68 enrolled

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Completed·NNICHD Global Network for Women's and Children's Health·N/A·NCT02409680·11,976 enrolled

Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women

Unknown status·SShanghai First Maternity and Infant Hospital··NCT03365466·200 enrolled

Show 1 more trial

Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT

Terminated·MMount Sinai Hospital, Canada·N/A·NCT00564174·88 enrolled

Complication2 trials

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting·UUniversity Hospital, Brest·Phase 3·NCT05198960·1,308 enrolled

The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population

Unknown status·WWomen's Hospital School Of Medicine Zhejiang University··NCT05089175·4,500 enrolled

Endometrial Cancer1 trial

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

Not yet recruiting·MMayo Clinic·Phase 4·NCT07281547·25 enrolled

Low Molecular Weight Heparin1 trial

Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.

Unknown status·DDr.Vandana Bansal·Phase 3·NCT01924104·400 enrolled

9 more indications

Ischemic stroke1 trial

Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds

Unknown status·XXijing Hospital·Phase 4·NCT04504864·400 enrolled

Polycythemia Vera1 trial

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Completed·PPharmaEssentia Japan K.K.·Phase 2·NCT04182100·29 enrolled

CABG1 trial

One-Month DAPT in CABG Patients

Recruiting·WWeill Medical College of Cornell University·Phase 3·NCT05997693·700 enrolled

Coronary Artery Bypass1 trial

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

Recruiting·DDolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.·Phase 3·NCT07195149·1,703 enrolled

Breast Cancer1 trial

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Recruiting·MMayo Clinic·Phase 2·NCT05557877·100 enrolled

Acute Coronary Syndrome1 trial

Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome

Unknown status·MMedical University of Warsaw·Phase 2·NCT06254391·40 enrolled

Growth1 trial

Trial of Early Screening Test for Pre-eclampsia and Growth Restriction

Completed·UUniversity College Dublin·Phase 4·NCT03674606·546 enrolled

Miscarriage1 trial

Hydroxychloroquine and Unexplained Recurrent Miscarriage

Completed·—·N/A·NCT04228263·156 enrolled

Unspecified1 trial

A Study to Evaluate P1101 in Japanese PV Patients

Completed·PPharmaEssentia Japan K.K.·Phase 3·NCT06002490·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Low-dose aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-dose aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-dose aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaEssentia Japan K.K. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPharmaEssentia Japan K.K.

Low-dose aspirin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q4 2030

Trials by Indication[1]

Preeclampsia5 trials

Pregnancy4 trials

Complication2 trials

Endometrial Cancer1 trial

Low Molecular Weight Heparin1 trial

Ischemic stroke1 trial

Polycythemia Vera1 trial

CABG1 trial

Coronary Artery Bypass1 trial

Breast Cancer1 trial

Acute Coronary Syndrome1 trial

Growth1 trial

Miscarriage1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News